Mechanism of Action for WELIREG™ (belzutifan)
![Mechanism of Action for WELIREG™ (belzutifan): WELIREG Binds to HIF-2α, Which Blocks Interaction With HIF-1β and May Reduce Downstream Activities of Cellular Proliferation Angiogenesis, and Tumor Growth](/static/mechanism-of-action-638debe5bbefb518d7a46fdceea9870e.webp)
![Mechanism of Action for WELIREG™ (belzutifan): WELIREG Binds to HIF-2α, Which Blocks Interaction With HIF-1β and May Reduce Downstream Activities of Cellular Proliferation Angiogenesis, and Tumor Growth](/static/mechanism-of-action-mobile-a702138a6e5dd2472fd38efee82140df.png)
HIF-2α = hypoxia-inducible factor 2 alpha; HIF-1β = hypoxia factor 1 beta.
The approval of WELIREG marks the first treatment option in a novel therapeutic class available for your appropriate patients with advanced RCC since 20151
Reference: 1. Yap NY, Khoo WT, Perumal K, et al. Practical updates in medical therapy for advanced and metastatic renal cell carcinoma. Urol Sci. 2018;29(3):120–128.
Connect with a Merck Associate